P3666 - Variations in Aspirin, NSAIDs, Statins, and Metformin Use After Colorectal Cancer Treatment between Early- and Late-Onset Colorectal Cancer Patients in an International Multicenter Study

Pakdee Rojanasopondist, MD¹, Ted Gooley, PhD², Cornelia Ulrich, PhD, MS³, Christopher I. Li, MD, PhD², David Shibata, MD⁴, Adetunji Toriola, MD, PhD⁵, Doratha Byrd, PhD, MPH⁶, Jane C. Figueiredo, PhD⁷, Biljana Gigic, PhD, MSc⁸, Sheetal Hardikar, MBBS, PhD, MPH³, Lyen Huang, MD, MPH⁹, Stacey Cohen, MD², Victoria Damerell, PhD⁸, Meghana V. Karchi, MPH¹⁰, Elizabeth H. Wood, MD⁴, Ildiko Strehli, PhD³, William M.. Grady, MD^2
1University of Washington, Seattle, WA; ²Fred Hutchinson Cancer Center, Seattle, WA; ³Huntsman Cancer Institute, Salt Lake City, UT; ⁴University of Tennessee Health Science Center, Memphis, TN; ⁵Washington University School of Medicine in St. Louis, St. Louis, MO; ⁶Moffitt Cancer Center, Tampa, FL; ⁷Cedars-Sinai Medical Center, Los Angeles, CA; ⁸Heidelberg University Hospital, Heidelberg, Baden-Wurttemberg, Germany; ⁹University of Utah and Huntsman Cancer Institute, Salt Lake City, UT; ¹⁰UTHSC, Southaven, MS

Introduction: The incidence of early-onset CRC (eoCRC), diagnosed < 50 years old, has recently been increasing. eoCRC patients face unique challenges after diagnosis and treatment that may shape their use of prescription or over-the-counter (OTC) medications. OTC medications may impact survivorship. For example, aspirin/NSAIDs have been associated with primary prevention for CRC, but also decreased mortality in CRC survivors. We compared the frequency of use of common OTC/prescription medications associated with CRC prevention between eoCRC and late-onset CRC (loCRC) patients following diagnosis and treatment.

Methods: We performed a retrospective cohort analysis of data from an international, multicenter study longitudinally following newly diagnosed colorectal cancer patients for 5-years. As part of this study, patients completed questionnaires about their use of aspirin, acetaminophen, ibuprofen, naproxen, celecoxib, statins, and metformin at the baseline, 6-, 12-, and 24-month timepoints. The rates of use for these medications were calculated for eoCRC and loCRC patients. Univariate and multivariable logistic regression models (controlling for stage, sex, BMI, smoking status, income, and education) were then performed.

Results: Of 3894 enrolled patients, 877 (23%) were eoCRC and 3336 (86%) completed a portion of the questionnaire at baseline, 2246 (58%) at 6-months, 2303 (59%) at 12-months, and 849 (22%) at 24-months (Table). For the evaluated medications, loCRC patients were significantly more likely to take regular aspirin, statins, and metformin at all timepoints, and significantly more likely to take baby-aspirin at baseline and 12-months and acetaminophen at 12-months. There was no difference in the rate of NSAID use between eoCRC and loCRC patients at any timepoint. Of patients who reported no history of heart disease, loCRC patients reported taking baby aspirin at a significantly higher rate than eoCRC at baseline (19% vs 3%, p=< 0.01) and at 12 months (14% vs 5%, p=0.04).

Discussion: In the 24-months following cancer treatment, loCRC patients took regular aspirin, statin, and metformin at a significantly higher rate than eoCRC. Among patients without heart disease, the frequency of baby aspirin use by loCRC patients remained higher than eoCRC at baseline and 12-months. These results suggest loCRC patients may be more inclined to take putative CRC preventing/survival modifying medications compared to eoCRC patients.


Disclosures:


Pakdee Rojanasopondist, MD¹, Ted Gooley, PhD², Cornelia Ulrich, PhD, MS³, Christopher I. Li, MD, PhD², David Shibata, MD⁴, Adetunji Toriola, MD, PhD⁵, Doratha Byrd, PhD, MPH⁶, Jane C. Figueiredo, PhD⁷, Biljana Gigic, PhD, MSc⁸, Sheetal Hardikar, MBBS, PhD, MPH³, Lyen Huang, MD, MPH⁹, Stacey Cohen, MD², Victoria Damerell, PhD⁸, Meghana V. Karchi, MPH¹⁰, Elizabeth H. Wood, MD⁴, Ildiko Strehli, PhD³, William M.. Grady, MD². P3666 - Variations in Aspirin, NSAIDs, Statins, and Metformin Use After Colorectal Cancer Treatment between Early- and Late-Onset Colorectal Cancer Patients in an International Multicenter Study, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.